Neuronautics is a biotech startup founded by Northwestern University professors to develop treatments and diagnostics for Alzheimer's disease. The company aims to halt or reverse the progression of Alzheimer's by preventing the formation of tau proteins that are believed to play a role in the disease. Neuronautics is testing thousands of drug compounds daily in animal models and hopes to begin clinical trials within a few years. However, the company has only raised $1.1 million to date and is seeking more private funding to accelerate its research.